BC Week In Review | Sep 12, 2011
Company News

Amira, Bristol-Myers deal

Amira Pharmaceuticals Inc. , San Diego, Calif.   Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.   Business: Pulmonary, Neurology, Cancer   Bristol-Myers completed its acquisition of Amira for $325 million in cash, plus up to $150...
BC Extra | Sep 10, 2011
Company News

Bristol-Myers spins out Amira assets

Bristol-Myers Squibb Co. (NYSE:BMY) created two newcos with assets from recently acquired inflammation company Amira Pharmaceuticals Inc. The first, Panmira Pharmaceuticals LLC (San Diego, Calif.), received Amira's prostaglandin D2 (PGD2) receptor ( CRTH2 ; GPR44 ) subtype...
BioCentury | Aug 1, 2011

Therapeutically adjacent

Bristol-Myers Squibb Co. 's acquisition of Amira Pharmaceuticals Inc. appears at first blush to net a single compound that has completed Phase I testing in a completely new disease area for the pharma, along with...
BC Week In Review | Jul 25, 2011
Company News

Amira, Bristol-Myers deal

Bristol-Myers will acquire Amira for $325 million in cash, plus up to $150 million in milestones. Bristol-Myers will gain Amira's AM152 , an oral lysophosphatidic acid receptor 1 ( LPA1 ) antagonist that has completed Phase I testing...
BC Innovations | Feb 10, 2011
Targets & Mechanisms

Getting a GRP on asthma

Researchers at the Duke University School of Medicine have shown that a small molecule blocker of gastrin-releasing peptide, originally identified as a tumor growth inhibitor by researchers at the National Cancer Institute , attenuates multiple parameters...
BC Week In Review | Jul 6, 2009
Clinical News

AM211: Interim Phase I data

Interim results from a blinded Phase I trial in healthy volunteers showed a single dose of oral AM211 had a sustained pharmacodynamic effect. In addition, blood concentrations of AM211 were found to be several multiples...
BioCentury | Jul 6, 2009
Product Development

Amira's lipid love affair

Spurred by academic research linking LPA1 to idiopathic pulmonary fibrosis, Amira Pharmaceuticals Inc. used its medicinal chemistry expertise in bioactive lipids to design antagonists for preclinical studies. The company presented proof-of-concept data in a mouse...
BC Week In Review | Apr 27, 2009
Clinical News

AM211: Phase I started

Amira began a double-blind, placebo-controlled Phase I trial to evaluate oral AM211 in 72 healthy volunteers Amira Pharmaceuticals Inc. , San Diego, Calif.   Product: AM211   Business: Inflammation   Molecular target: Prostaglandin D2 (PGD2) receptor...
BC Week In Review | Jan 12, 2009
Clinical News

Amira preclinical data

AM211 demonstrated a good safety profile in dog and rat GLP toxicity studies. The company plans to submit an IND this half. AM211 is an oral small molecule antagonist of prostaglandin D2 (PGD2) receptor ( CRTH2...
Items per page:
1 - 9 of 9